Palifermin vs Teriparatide
Head-to-head comparison of Palifermin (Recombinant Human Keratinocyte Growth Factor (KGF, FGF7)) and Teriparatide (Parathyroid Hormone (1-34)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Palifermin | Teriparatide |
|---|---|---|
| Category | Recovery & Healing | Recovery & Healing |
| Full Name | Recombinant Human Keratinocyte Growth Factor (KGF, FGF7) | Parathyroid Hormone (1-34) |
| Molecular Weight | 16.3 kDa | 4117 Da |
| Half-Life | 4–6 hours | about 1 hour |
| Amino Acids | 140 | 34 |
| Typical Dose | 60 µg/kg/day | 20 mcg daily |
| Route | Intravenous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 250 | 1200 |
| Research Status | Clinical | Clinical |
Palifermin Benefits
- ✓epithelial protection
- ✓mucosal regeneration
- ✓barrier restoration
- ✓reduced inflammatory injury
Teriparatide Benefits
- ✓stimulates bone formation
- ✓supports fracture union
- ✓improves bone mineral density
- ✓may aid bone remodeling
Palifermin Dosing
IV 60 µg/kg/day for 3 days before and 3 days after insult|research protocols vary|short courses only
Teriparatide Dosing
20 mcg subcutaneous daily|intermittent anabolic exposure|monitor calcium and vitamin D status
Palifermin Side Effects
- ⚠rash
- ⚠taste changes
- ⚠edema
- ⚠arthralgia
Teriparatide Side Effects
- ⚠hypercalcemia
- ⚠nausea
- ⚠dizziness
Research Overview
Palifermin
Palifermin is clinically established for mucosal protection and has been studied for epithelial repair in other tissues. The strongest evidence is for epithelial resilience and regeneration rather than direct dermal remodeling.
Teriparatide
Teriparatide has extensive clinical literature showing anabolic effects on bone and investigational use in delayed unions and nonunions. It is one of the best-studied peptide-based options for skeletal recovery.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.